{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:15:18Z","timestamp":1784297718753,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The potent inhibitory action on bone resorption and concomitant stimulatory effect on bone modeling make denosumab (DEN) as a possible alternative to anabolic drugs for treatment of severe osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the real-world effectiveness of DEN and teriparatide (TPTD) in patients with severe osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 357 patients (300 females, 57 males; mean age 70.2 \u00b1 10.7 years) attending a referral center for osteoporosis in the period between July 2021 and June 2025. All the patients had indications for treatment with TPTD according to the national drug reimbursement criteria. However, 198 patients were treated with TPTD for 24 months, whereas 159 patients received DEN for contraindications to TPTD (110 cases), patient preference (39 cases) or side effects after few doses of the drug (10 cases). Patients were evaluated for clinical\/morphometric VFs and non-vertebral fractures (NVFs) at baseline and after 24 months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 34 patients (9.5%) developed new VFs (clinical in 13 cases) and 7 patients (2.0%) experienced NVFs. The risk of new VFs was significantly associated with vertebroplasty procedure (odds ratio 2.409; p=0.037). Moreover, new VFs occurred less frequently in patients treated with TPTD as compared to DEN (12\/198 vs. 22\/159; p=0.013). In the multivariable analysis, the favorable effect of TPTD on risk of VFs was still significant after correction for vertebroplasty (odds ratio 0.39; confidence interval 95% 0.19-0.83; p=0.014). No significant difference in NVFs was found between DEN and TPTD (2\/159 vs. 5\/198; p=0.468).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study shows that DEN might be less effective than TPTD in preventing VFs in patients with severe osteoporosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1744054","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:26:35Z","timestamp":1773725195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Maria Francesca","family":"Birtolo","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Piasentier","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Daniela","family":"Dutu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital","place":["Rozzano, Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Vena","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology and Diabetology Unit, Humanitas Gavazzeni","place":["Bergamo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Morenghi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Biostatistics Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Pigni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia Maria Silvana","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fanti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Capo","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Tomei","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Brembilla","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fornari","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Laghi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Radiology Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letterio Salvatore","family":"Politi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Radiology Department, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Bossi","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetology Unit, Humanitas Gavazzeni","place":["Bergamo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gerardo Antonio","family":"Lania","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Endocrinology, Diabetology, Medical Andrology Unit, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-Based Guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomized controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06863-y","article-title":"Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study","volume":"34","author":"EvertsGraber","year":"2023","journal-title":"Osteoporos Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221105009","article-title":"Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study","volume":"14","author":"Adami","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11657-024-01447-7","article-title":"Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2024","journal-title":"Arch Osteoporos"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06708-8","article-title":"Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension","volume":"34","author":"Hans","year":"2023","journal-title":"Osteoporos Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab Jun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-015-0428-y","article-title":"Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP)","volume":"27","author":"Moretti","year":"2015","journal-title":"Aging Clin Exp Res Oct"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res Jan"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02280-4","article-title":"Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study","volume":"47","author":"Jaarah","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"key":"B18","unstructured":""},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0078-1","article-title":"A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men","volume":"12","author":"Mikyas","year":"2014","journal-title":"Appl Health Econ Health policy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.23736\/s0391-1977.20.03137-5","article-title":"Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab","volume":"45","author":"Betella","year":"2020","journal-title":"Minerva endocrinologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02082-8","article-title":"A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS","volume":"46","author":"Adami","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04275-y","article-title":"A practical use of bone turnover markers in management of patients with skeletal fragility","volume":"89","author":"Brunetti","year":"2025","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2567-3","article-title":"Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening","volume":"25","author":"Clark","year":"2014","journal-title":"Osteoporos Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","article-title":"New advances in imaging osteoporosis and its complications","volume":"42","author":"Griffith","year":"2012","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11657-019-0577-2","article-title":"Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry","volume":"14","author":"Engelke","year":"2019","journal-title":"Arch Osteoporos"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2354734","DOI":"10.1001\/jamanetworkopen.2023.54734","article-title":"Denosumab and the risk of diabetes in patients treated for osteoporosis","volume":"7","author":"Huang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3972","article-title":"A pooled analysis of fall incidence from placebo-controlled trials of denosumab","volume":"35","author":"Chotiyarnwong","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2017.05.007","article-title":"Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial","volume":"20","author":"Tsai","year":"2017","journal-title":"J Clin Densitom"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19260","article-title":"Denosumab for osteoporosis in older adults in long-term care: A randomized trial","volume":"73","author":"Greenspan","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2022.05.011","article-title":"Polypharmacy in osteoporosis treatment","volume":"38","author":"McConnell","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02395-2","article-title":"A practical approach for anabolic treatment of bone fragility with romosozumab","volume":"47","author":"Cianferotti","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04434-1","article-title":"Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures","volume":"90","author":"Colle","year":"2025","journal-title":"Endocrine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman","year":"2014","journal-title":"Curr osteoporosis Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11478-4","article-title":"ESR Essentials: percutaneous bone consolidation-practice recommendations by the European Society of Musculoskeletal Radiology","volume":"35","author":"Le Corroller","year":"2025","journal-title":"Eur Radiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13018-022-03038-z","article-title":"Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures, especially in Eastern Asia: a systematic review and meta-analysis","volume":"17","author":"Dai","year":"2022","journal-title":"J Orthop Surg Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10807-3","article-title":"Risk of adjacent level fracture after percutaneous vertebroplasty and kyphoplasty vs natural history for the management of osteoporotic vertebral compression fractures: a network meta-analysis of randomized controlled trials","volume":"34","author":"Essibayi","year":"2024","journal-title":"Eur Radiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/os.14087","article-title":"A real-world study of denosumab for reducing refracture risk after percutaneous vertebral augmentation","volume":"16","author":"Zou","year":"2024","journal-title":"Orthopaedic surgery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.wnsx.2023.100153","article-title":"Analysis of radiologic and clinical outcome in acute osteoporotic vertebral compression fracture: Single-agent teriparatide vs. teriparatide with subsequent vertebroplasty","volume":"18","author":"Jin","year":"2023","journal-title":"World Neurosurg X"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-024-08349-9","article-title":"Teriparatide alone versus vertebroplasty on pain control and radiographic outcomes after osteoporotic vertebral compression fracture","volume":"33","author":"Chen","year":"2024","journal-title":"Eur Spine J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2432041","DOI":"10.1001\/jamanetworkopen.2024.32041","article-title":"Conservative treatments in the management of acute painful vertebral compression fractures: A systematic review and network meta-analysis","volume":"7","author":"Alimy","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocrine Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1336075","article-title":"Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis","volume":"15","author":"Dong","year":"2024","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J Bone Miner Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1744054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:26:36Z","timestamp":1773725196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1744054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":47,"alternative-id":["10.3389\/fendo.2026.1744054"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1744054","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"1744054"}}